Off Into Weekend, As Early Work Undone
ResMed (ASX:RMD) fell 8.29% on Friday and is 3.09% lower for the week after a strong run. The company reported a solid Q4, with FY26 revenue up 10% to $5.7b, gross Q4 margin 62.3%, FY EPS up 17% to $11.17, and a 10% dividend increase to $0.66. Morgan Stanley downgraded to Equal Weight and cut its price target, citing cooling growth and Philips’ potential US return in 2027.
How this was made
The 30-second read
Why it matters
The market appears to be shifting from “results are holding up” to “growth trajectory and competitive risk are uncertain,” reinforced by a broker downgrade and a small margin/operating income miss vs consensus.
Market read
Traders get a concrete catalyst mix: a same-week earnings backdrop plus a fresh downgrade and a competitive narrative that can drive multiple compression even when headline results look solid.
What to watch
The article notes a Q4 beat on EPS and raised dividend; if investors focus on cash return and margin durability, the downside narrative may weaken.
Background
ResMed’s recent run-up into earnings was followed by a sharp reversal, despite reporting solid FY26 and Q4 results.
Ticker impact
ResMed (RMD) fell 8.29% on Friday after a Q4 beat, with Morgan Stanley downgrading to Equal Weight and trimming its price target.
Near term, downside bias persists while the downgrade and competitive narrative dominate; upside likely requires evidence that growth is re-accelerating or the Philips overhang fades.
The article cites a specific broker downgrade, a small but real operating income and gross margin miss vs consensus, and frames valuation as cheap yet unsupported by sustained buying.
Market effects
Signals that even strong medtech earnings can be sold if growth expectations cool and competitive threats re-emerge.
ASX 200 repositioning, with ResMed singled out as a relative laggard after a strong prior week.
Read-across to global respiratory/medical device peers where valuation support depends on sustained growth.
Counterpoint
The downgrade may be late and the valuation is already near decade lows, so the sell-off could be an overreaction to a non-imminent competitive risk.
Key entities
- companyResMed
ASX-listed medical device maker whose shares dropped sharply after Q4 results and a Morgan Stanley downgrade.
- financial_institutionMorgan Stanley
Downgraded ResMed to Equal Weight and trimmed its price target, citing cooling growth and Philips’ potential US return.
- companyPhilips
Competitive threat referenced as potentially returning to the US market in 2027, creating a medium-term overhang.
